Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thankyou
It's hard to believe you can have c£900,000 revenues for full year (confirmed as being likely to be achieved twice) an a Conservative pipeline of £1,500,000 amd yet the entire business valued at only £1.5mln!
Project runs until October 2025. Presumably there will be indications much earlier as to the success of the trials
Good morning Trench
Is there an end date for the trials please ?
Interesting that DoseMeRx have reposted this PYC tweet :
'Check out this insightful article from our partner @DoseMeApp highlighting the vital role of #precisionmedicine in #oncology and beyond'
I feel that a commercial deal between the two companies is likely if the G-CSF trials go well
Same here, I have close to 1% and holding
Likewise Andrew I'm currently holding over 1% and have no intention of selling!
Hello Andrew
Ridiculous were only trading on 1.5 x expected earning !!
Hi Laura,
Have just done the same. Long term holder, can see some momentum here for the first time in a while. I like how positive Peter has been in recent months, which adds to my confidence levels!
With revenues expected to be £900,000- 1mln and pipeline increased to £1.5mln I have used some of the new ISA money to add more
Evidence-based interventions, such as improved early detection and education programmes, will help to save lives and prevent ill health from prostate cancer in the years to come,” added James, a professor of prostate cancer research at the Institute of Cancer Research, London, and a consultant clinical oncologist at the Royal Marsden NHS foundation trust.
James said there was a global need for new and improved ways to test for the disease, to reduce overdiagnosis and overtreatment while detecting potentially lethal tumours earlier
This brings PYC technology well into focus
https://www.theguardian.com/society/2024/apr/04/prostate-cancer-cases-worldwide-diagnoses-deaths-2040-study
Nice summary again,really nice to have mew ideas / points of view
Laura I don't think we need to be speculative. PYC is undervalued but the market is where it is at present ( poised to breakout ) . Let's wait for the next contract win and update either one of which is likely to be very soon. The Board are clearly aware as never before of the need to keep shareholders in the loop and the importance of news flow. The expansion of their corporate objectives is really good news and once factored in will undoubtedly see a rerate of the share price. Many of us have waited a long time for the company to mature. It is now fast approaching that point and I have no doubt that the current CEO will endeavour to manage significant growth in the short to medium term. It's good to see more interest in the shares of late. That said I do agree with your assertion that a successful outcome to a Dosing App would be a massive bonus that could well present further opportunities. What is abundantly clear is that the Board appreciate market perception and trust need to be better understood and restored and are.
That s an error ..up 100% over last 2 days
Sorry
Acceptance from NICE for one of their technology tests via RNS yesterday
Shows what could happen with our precision dosing app
Ant
I have only just noticed that this 50% increase In pipeline is excluding biostatistics work ....(Pete said in results there will be an update before June)
Company's pipeline of potential new business now stands at over £1.5m (not risk weighted and EXCLUDING Biostatistics), counting only opportunities where a specific project has been discussed with a client
Yes Ant
On HL its nearly impossible to buy ..even last week it was difficult to get q quote for more than £3000
Today there's nothing (although HL can be a bit erratic)
DeBull You are quite right of course, but buying is not that easy at present. Try a buy or two yourself just to check the market.
To follow on fro others,really good posts Ant
Yesterday there was already more buys than sells before the flurry,same the day before when alot of buys shown as sells at 1.27p (been going on on weeks)
Yesterday
The buys were often round numbers and within 2 -5 minutes of each other ...not sure ìf this was to break down one trade or just coincidence or maybe of was difficult to buy them + in one go ?
Https://invst.ly/149bbu
Buyers moved in y'day ,looking to close above 1.35 -1.40 ,poss rise to the 50 ema on the weekly c 1.85
Great post this ANT
Ant, nice paragraph there.
Have you migrated here from elsewhere?
Am i right in thinking you may have some historical ties with the stock?
The drop yesterday was i think in part after a few days of selling. I did not see any B&I swaps going through, normally you can match largish trades, discounting a few shares per trade with a B&I.
We then had over 15 buys ranging from a few hundred to over 1 thousand £'s all very much needed, However, seeing trades of 250k+ is what is required.
AACR Annual meeting is in San Diego 5th to 10th April, i wonder if PYC will attend, or submit abstract?
Hi I've been sold on the technology for years Laura. Systems Biology/Physiomics was in its infancy over 20 years ago. Laura, The main reason its adoption has been so slow ( not just limited to PYC ) is that tried and tested animal models have always ( up until quite recently) been the only way to steer a passage through the well charted waters ( procedural requirements) of The FDA , MRHA et al. During this time we have witnessed all else in computers including and not limited to drug discovery and rational drug design.
I believe that the new CEO is a force for good, he appears to display much needed enthusiasm something that has been lacking in his predecessors . The original aim was to create working tools/models, for the deliverance of Personalised Medicine and dosing regimes. It looks as though (Not before time) this will now become a reality. Lets hope so The market sector presents a uniquely massive opportunity to successful participants.
As with everything associated with drug development and discovery it takes time to garner support and acceptance for new technologies. Over a 100 projects later and we are beginning to see the kind of peer group acceptance of PYC's tech. It can only be for the good It speaks volumes to me!
Evening Ant
Yes. ,now it is proven technology and more and more clients are using PYC thru should no longer just benefit from the service contract but should negotiate some royalties in conjunction with the client . The time and cost saved by using OUC should be reflected in add- ons In my view
Company's Virtual Tumour? technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies has been confirmed by over 100 projects
It will only happen as traction and confidence in their technology grows and the need to use it to comply with regulatory requirements . There after it will the subject of their negotiating skills which are currently under the microscope and far from the best tool in their portfolio! Just my opinion but hopefully their confidence to put in deal making clauses will increase away from a lets do a deal at all costs mentality. They are saving bio's and small pharma cos significant amounts of expenditure in areas where attrition is greatest. Its looking good and long overdue!